NCT02242942 · BASELINE

Baseline characteristics

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia · Source last updated 2025-11-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
216
group Id
BG001
value
216
group Id
BG002
value
13
group Id
BG003
value
445
units
Participants

groups

description
Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
id
BG000
title
Obinutuzumab + Chlorambucil
description
Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
id
BG001
title
Obinutuzumab + Venetoclax
description
Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
id
BG002
title
Safety Run-in Obinutuzumab + Venetoclax
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
8.0
value
71.1
group Id
BG001
spread
8.2
value
71.1
group Id
BG002
spread
7.8
value
75.4
group Id
BG003
spread
8.1
value
71.1
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
Years
classes
categories
measurements
group Id
BG000
value
73
group Id
BG001
value
70
group Id
BG002
value
5
group Id
BG003
value
148
title
Female
measurements
group Id
BG000
value
143
group Id
BG001
value
146
group Id
BG002
value
8
group Id
BG003
value
297
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
22
group Id
BG002
value
1
group Id
BG003
value
43
title
Hispanic or Latino
measurements
group Id
BG000
value
172
group Id
BG001
value
165
group Id
BG002
value
12
group Id
BG003
value
349
title
Not Hispanic or Latino
measurements
group Id
BG000
value
19
group Id
BG001
value
22
group Id
BG002
value
0
group Id
BG003
value
41
title
Not Stated
measurements
group Id
BG000
value
5
group Id
BG001
value
7
group Id
BG002
value
0
group Id
BG003
value
12
title
Unknown
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
4
title
Black or African American
measurements
group Id
BG000
value
0
group Id
BG001
value
3
group Id
BG002
value
0
group Id
BG003
value
3
title
Native Hawaiian or other Pacific Islande
measurements
group Id
BG000
value
18
group Id
BG001
value
20
group Id
BG002
value
0
group Id
BG003
value
38
title
Unknown
measurements
group Id
BG000
value
194
group Id
BG001
value
192
group Id
BG002
value
13
group Id
BG003
value
399
title
White
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants

Complete source fields

denoms

counts
group Id
BG000
value
216
group Id
BG001
value
216
group Id
BG002
value
13
group Id
BG003
value
445
units
Participants

groups

description
Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
id
BG000
title
Obinutuzumab + Chlorambucil
description
Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
id
BG001
title
Obinutuzumab + Venetoclax
description
Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
id
BG002
title
Safety Run-in Obinutuzumab + Venetoclax
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
8.0
value
71.1
group Id
BG001
spread
8.2
value
71.1
group Id
BG002
spread
7.8
value
75.4
group Id
BG003
spread
8.1
value
71.1
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
Years
classes
categories
measurements
group Id
BG000
value
73
group Id
BG001
value
70
group Id
BG002
value
5
group Id
BG003
value
148
title
Female
measurements
group Id
BG000
value
143
group Id
BG001
value
146
group Id
BG002
value
8
group Id
BG003
value
297
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
22
group Id
BG002
value
1
group Id
BG003
value
43
title
Hispanic or Latino
measurements
group Id
BG000
value
172
group Id
BG001
value
165
group Id
BG002
value
12
group Id
BG003
value
349
title
Not Hispanic or Latino
measurements
group Id
BG000
value
19
group Id
BG001
value
22
group Id
BG002
value
0
group Id
BG003
value
41
title
Not Stated
measurements
group Id
BG000
value
5
group Id
BG001
value
7
group Id
BG002
value
0
group Id
BG003
value
12
title
Unknown
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
4
title
Black or African American
measurements
group Id
BG000
value
0
group Id
BG001
value
3
group Id
BG002
value
0
group Id
BG003
value
3
title
Native Hawaiian or other Pacific Islande
measurements
group Id
BG000
value
18
group Id
BG001
value
20
group Id
BG002
value
0
group Id
BG003
value
38
title
Unknown
measurements
group Id
BG000
value
194
group Id
BG001
value
192
group Id
BG002
value
13
group Id
BG003
value
399
title
White
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice